ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: A report of the american college of cardiology foundation/american heart association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): Developed in collaboration with the american academy of family physicians

Circulation

Volumn 120, Issue 13, 2009, Pages 1296-1336

  Redberg, Rita F ^a   Benjamin, Emelia J ^a   Bittner, Vera ^a   Braun, Lynne T ^b   Goff, David C ^c   Havas, Stephen ^c   Labarthe, Darwin R ^c   Limacher, Marian C ^d   Lloyd Jones, Donald M ^d   Mora, Samia ^d   Pearson, Thomas A ^d   Radford, Martha J ^d   Smetana, Gerald W ^e   Spertus, John A ^f   Swegler, Erica W ^f   Masoudi, Frederick A ^g   Bonow, Robert O ^g   Delong, Elizabeth ^d   Grady, Kathleen ^d   Green, Lee A ^d   Jenkins, Kathy J ^d   Loth, Ann R ^d   Peterson, Eric D ^d   Rumsfeld, John S ^d   Shahian, David M ^d   more..

^a American Association of Cardiovascular and Pulmonary Rehabilitation Representative   (United States)

^b Preventive Cardiovascular Nurses Association Representative

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^d AHA Task Force on Performance Measures Liaison ^*

^e AMERICAN COLLEGE OF PHYSICIANS   (United States)

^f AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

^g Former Task Force Chair during This Writing Effort

Author keywords

ACCF AHA Performance Measures; Cardiovascular disease; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; FISH OIL; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UBIQUINONE;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COUNSELING; DIABETES MELLITUS; DIETARY INTAKE; DYSLIPIDEMIA; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE; LOW DRUG DOSE; MEDICAL SOCIETY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PHYSICIAN; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SMOKING; SMOKING CESSATION; STROKE;

ADULT; BENCHMARKING; CARDIOLOGY; CARDIOVASCULAR DISEASES; HUMANS; QUALITY OF HEALTH CARE;

EID: 70349852672     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.192617     Document Type: Review

References (103)

1. Institute of Medicine of the National Academies Committee on Quality of Health Care in America, Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 2001.
2. Bonow RO, Bennett S, Casey DE Jr, et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures). J Am Coll Cardiol. 2005;46: 1144-1178 (Pubitemid 41316528)
3. American College of Cardiology, American Heart Association, Physician Consortium for Performance Improvement. Clinical Performance Measures: Chronic Stable Coronary Artery Disease. Available at: http:// www.ama-assn.org/ama1/pub/ upload/mm/370/cadminisetjune06.pdf. Accessed July 14, 2008.
4. American Medical Association. Physician Consortium for Performance Improvement. Clinical Performance Measures: Hypertension. Available at: http://www.ama-assn.org/ama1/pub/upload/mm/370/hypertension-8-05.pdf. Accessed July 14, 2008.
5. Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol. 2006;47:236-265
6. Thomas RJ, King M, Lui K, et al. AACVPR/ACC/AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services. J Am Coll Cardiol. 2007;50:1400-1433
7. Estes NA 3rd, Halperin JL, Calkins H, et al. ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonval-vular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation). J Am Coll Cardiol. 2008;51:865-884
8. Spertus JA, Eagle KA, Krumholz HM, et al. American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. J Am Coll Cardiol. 2005;45:1147-1156
9. Krumholz HM, Brindis RG, Brush JE, et al. Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Circulation. 2006;113:456-462
10. Newman WP 3rd, Wattigney W, Berenson GS. Autopsy studies in United States children and adolescents: relationship of risk factors to atherosclerotic lesions. Ann N Y Acad Sci. 1991;623:16-25.
11. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999;281:727-735
12. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282:2012-2018
13. Daviglus ML, Stamler J, Pirzada A, et al. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. JAMA. 2004;292:1588-1592
14. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-798
15. Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000;343:16-22.
16. Daviglus ML, Liu K, Pirzada A, et al. Favorable cardiovascular risk profile in middle age and health-related quality of life in older age. Arch Intern Med. 2003;163:2460-2468
17. Daviglus ML, Liu K, Greenland P, et al. Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to Medicare costs. N Engl J Med. 1998;339:1122-1129
18. Kavey RE, Daniels SR, Lauer RM, et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003;107:1562-1566
19. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statis-tics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
20. Hollister D Jr, Romanello JM, Smith ML, et al. Use of physician-specific data and flow sheets to improve compliance with preventive and screening health care measures. Conn Med. 2006;70:613-620
21. Dove JT. The electronic health record: the time is now. Am Heart Hosp J. 2005;3:193-200.
22. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106: 388-391
23. Guide to Clinical Preventive Services 2007: Recommendations of the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality. Available at: https://www.oxhp.com/secure/materials/ member/adult-preventive. pdf. Accessed June 3, 2009.
24. De BG, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis. 2003;171:145-155
25. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115:1481-1501
26. JBS 2: Joint British Societies? guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(suppl 5):v1-v52.
27. Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel III) final report Circulation 2002 106 3143-3421
28. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252
29. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292:1433-1439
30. Akesson A, Weismayer C, Newby PK, et al. Combined effect of low-risk dietary and lifestyle behaviors in primary prevention of myo-cardial infarction in women. Arch Intern Med. 2007;167:2122-2127
31. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083-2093
32. Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial. Circulation. 2009;119:2026-2031
33. Hark L, Deen D Jr. Taking a nutrition history: a practical approach for family physicians. Am Fam Physician. 1999;59:1521-1522
34. Lloyd-Jones DM, Nam BH, D?Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291:2204-2211
35. Murabito JM, Pencina MJ, Nam BH, et al. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA. 2005;294:3117-3123
36. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356: 2388-2398
37. Grandes G, Sanchez A, Sanchez-Pinilla RO, et al. Effectiveness of physical activity advice and prescription by physicians in routine primary care: a cluster randomized trial. Arch Intern Med. 2009;169: 694-701.
38. McTigue KM, Harris R, Hemphill B, et al. Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;139:933-949
39. Albu JB, Murphy L, Frager DH, et al. Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes. 1997;46:456-462
40. Wajchenberg BL, Giannella-Neto D, da Silva ME, et al. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res. 2002;34: 616-621
41. Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in prevalence, treatment, and control of hypertension: United States, 1999-2002. MMWR Morb Mortal Wkly Rep. 2005;54:7-9.
42. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125
43. Dhruva SS, Redberg RF. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions. Arch Intern Med. 2008;168:136-140
44. Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004;291:2243-2252
45. Hall LM, Jung RT, Leese GP. Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ. 2003;326:251-252
46. Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res. 2008;8:60.
47. Berry JD, Lloyd-Jones DM, Garside DB, et al. Framingham risk score and prediction of coronary heart disease death in young men. Am Heart J. 2007;154:80-86
48. Vasan RS, Sullivan LM, Wilson PW, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med. 2005;142:393-402.
49. Cavanaugh-Hussey MW, Berry JD, Lloyd-Jones DM. Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool. Prev Med. 2008;47:619-623
50. Wilson PW, D?Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847
51. D?Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753
52. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
53. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-619
54. Wolf PA, D?Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318
55. Lumley T, Kronmal RA, Cushman M, et al. A stroke prediction score in the elderly: validation and Web-based application. J Clin Epidemiol. 2002;55:129-136
56. Chambless LE, Heiss G, Shahar E, et al. Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2004;160:259-269 (Pubitemid 39006782)
57. Tanne D, Yaari S, Goldbourt U. Risk profile and prediction of long-term ischemic stroke mortality: a 21-year follow-up in the Israeli Ischemic Heart Disease (IIHD) Project. Circulation. 1998;98:1365-1371
58. Pencina MJ, D?Agostino RB Sr, D?Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172
59. Pencina MJ, D?Agostino RB Sr, D?Agostino RB Jr, et al. Comments on ?Integrated discrimination and net reclassification improvements practical advice.? Stat Med. 2008;27:207-212
60. D?Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994;25:40-43
61. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049-1056
62. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373: 1849-1860
63. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295: 306-313
64. Mora S. Aspirin therapy in women: back to the ABC?s. Circ Cardiovasc Qual Outcomes. 2009;2:63-64
65. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-2141
66. Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007; 297:2018-2024 (Pubitemid 46740354)
67. Lee CD, Folsom AR, Pankow JS, et al. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation. 2004;109:855-860
68. Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart. 2004;90:1398-1403
69. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653
70. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358:2630-2633
71. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853
72. McCormack J, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. BMJ. 2000;320:1720-1723
73. Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359: 1565-1576
74. National Diabetes Quality Improvement Alliance. Performance Measurement Set for Adult Diabetes. Available at: http://www-nehc.med. navy.mil/prevmed/ Diabetes/Document%20Folders/DIABETES/CPG/ DQIA.msrs.pdf. Accessed December 11, 2007
75. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713
76. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696
77. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82-96.
78. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation. 2007; 116:1081-1093
79. US Department of Health and Human Services, US Department of Agriculture. Dietary Guidelines for Americans, 2005. 6th ed. HHS Publication No. HHS-ODPHP-2005-01-DGA-A. Washington, DC: US Government Printing Office; 2005.
80. Appel LJ, Moore TJ, Obarzanek E, et al, for the DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336:1117-1124
81. Your Guide to Lowering Your Blood Pressure with DASH. US Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood Institute. Available at: http:// www.nhlbi.nih.gov/health/public/ heart/hbp/dash/new-dash.pdf. Accessed July 14, 2008.
82. US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996. Available at: http://www.cdc.gov/nccdphp/sgr/pdf/ sgrfull.pdf. Accessed July 14, 2008.
83. American Medical Association Physician Consortium for Performance Improvement. Clinical Performance Measures: Preventive Care and Screening Tobacco Use. Available at: http://www.ama-assn.org/ama1/ pub/upload/mm/370/ preventiveset-12-05.pdf. Accessed July 14, 2008.
84. Conroy MB, Majchrzak NE, Silverman CB, et al. Measuring provider adherence to tobacco treatment guidelines: a comparison of electronic medical record review, patient survey, and provider survey. Nicotine Tob Res. 2005;7(suppl 1):S35-S43.
85. Centers for Disease Control and Prevention (CDC). Tobacco use among adults United States, 2005. MMWR Morb Mortal Wkly Rep. 2006; 55:1145-1148
86. Centers for Disease Control and Prevention (CDC). Cigarette smoking-attributable morbidity United States, 2000. MMWR Morb Mortal Wkly Rep. 2003;52:842-844
87. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2004;CD000165.
88. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2004;CD000031.
89. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2007;CD006103.
90. Reeves GR, Wang TY, Reid KJ, et al. Dissociation between hospital performance of the smoking cessation counseling quality metric and cessation outcomes after myocardial infarction. Arch Intern Med. 2008; 168:2111-2117
91. Ranney L, Melvin C, Lux L, et al. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006;145:845-856
92. National Heart, Lung, and Blood Institute, National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Available at: http://www.nhlbi.nih.gov/guidelines/obesity/ob-gdlns.pdf. Accessed July 14, 2008
93. US Preventive Services Task Force. Screening for obesity in adults: recommendations and rationale. Ann Intern Med. 2003;139:930-932
94. Jakicic JM, Clark K, Coleman E, et al. American College of Sports Medicine position stand: appropriate intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2001;33:2145-2156
95. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290:199-206.
96. Institute for Clinical Systems Improvement. Health Care Guideline: Preventive Services for Adults. Available at: http://www.icsi.org/ guidelines-and-more/preventive-services-for-adults-4.html. Accessed July 14, 2008.
97. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053
98. US Preventive Services Task Force. Screening for Lipid Disorders in Adults: US Preventive Services Task Force Recommendation Statement. AHRQ Publication No. 08-05114-EF-2. Agency for Healthcare Research and Quality. Available at http://www.ahrq.gov/clinic/uspstf08/ lipid/lipidrs.htm. Accessed July 14, 2008.
99. D?Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-187
100. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396-404
101. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157-160
102. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-126
103. National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Available at: http://www.nhlbi.nih.gov/guidelines/obesity/prctgd-c.pdf. Accessed July 14, 2008.